- Home
- IBTA vs EVMN Comparison
IBTA vs EVMN Comparison
Compare IBTA & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | EVMN |
|---|---|---|
| Founded | 2011 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.3M | 825.5M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBTA | EVMN |
|---|---|---|
| Price | $30.55 | $22.78 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $28.50 | ★ $43.88 |
| AVG Volume (30 Days) | 122.6K | ★ 288.0K |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $342,389,000.00 | N/A |
| Revenue This Year | $2.02 | N/A |
| Revenue Next Year | $8.96 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.10 | $13.89 |
| 52 Week High | $56.60 | $33.20 |
Technical Indicators
Market Signals| Indicator | IBTA | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 42.32 |
| Support Level | $21.23 | $21.39 |
| Resistance Level | $35.11 | $23.08 |
| Average True Range (ATR) | 2.01 | 1.56 |
| MACD | -0.97 | -0.20 |
| Stochastic Oscillator | 16.26 | 20.44 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc operates a digital promotions platform, the Ibotta Performance Network (IPN), which connects consumer packaged goods (CPG) brands with consumers through a network of publishers. It sources digital offers from clients and distributes them via its technology platform, earning revenue when promotions result in consumer transactions. The platform supports offers across grocery and general merchandise categories, including toys, clothing, beauty, electronics, pet, and home products. The majority of its revenues is derived from the fees charged to clients when consumers redeem offers on the IPN by purchasing promoted products.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.